Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis

Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials (RCTs) have shown mixed results regarding the use of this medication.

Saved in:

Bibliographic Details
Main Authors:	Luis O. S. Nogueira, Roberto A. S. V. Mazetto, Maria L. R. Defante, Vânio L. J. Antunes, Ocílio Ribeiro Gonçalves, Angela Maria Sandini Corso, Marcus V. Della Coletta, Dayany Leonel Boone, Walderico Silva Machado Filho, Vanderci Borges, Henrique Ballalai Ferraz
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações 2025-04-01
Series:	Arquivos de Neuro-Psiquiatria
Subjects:	Glucagon-Like peptide 1 Parkinson Disease Randomized Controlled Trial Movement Disorders Meta-Analysis
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1806824
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
by: Brian Finan, et al.
Published: (2025-06-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Role of serum fasting glucagon in hypothyroidism-related nonalcoholic fatty liver disease
by: Mervat M. El-Eshmawy, et al.
Published: (2025-03-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches
by: Tsuguka Matsuda, et al.
Published: (2023-11-01)

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01)

Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications
by: Meghan Brennan, et al.
Published: (2025-04-01)

Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control
by: Seung Hee Lee, et al.
Published: (2025-07-01)

Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
by: Luis Alberto Vigara, et al.
Published: (2024-11-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
by: Kateri J. Spinelli, et al.
Published: (2025-06-01)

Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study
by: Max D. Sandler, et al.
Published: (2025-06-01)

The neglected PCK1/glucagon (inter)action in nutrient homeostasis beyond gluconeogenesis: Disease pathogenesis and treatment
by: Romina Bertinat, et al.
Published: (2025-04-01)

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)

Autophagy-lysosome pathway in insulin & glucagon homeostasis
by: Yi Wu, et al.
Published: (2025-02-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and ratsResearch in context
by: Rune Ehrenreich Kuhre, et al.
Published: (2025-08-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Sex and age differences in cortisol levels during glucagon stimulation test in children
by: Camilla Borghammar, et al.
Published: (2025-05-01)

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release
by: Nicholas C. Bank, MD, et al.
Published: (2025-07-01)

Different light/dark condition modulation of the daily rhythm of insulin and glucagon in dogs
by: Claudia Giannetto, et al.
Published: (2025-06-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
by: Yu-Xuan Yao, et al.
Published: (2025-12-01)

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence
by: Panagiotis Stachteas, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting
by: Bárbara Ferreira, et al.
Published: (2025-06-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Yiwen Liu, et al.
Published: (2025-05-01)

Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study
by: Brittany Johnson, et al.
Published: (2025-04-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Decreased expression of insulin-degrading enzyme increases gluconeogenesis and glucose production in cultured hepatocytes administered with glucagon
by: Carlos M. González-Casimiro, et al.
Published: (2025-05-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)